Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Alogliptin shows no significant improvement in glycemic control for pediatric T2DM
Última actualización 9 de septiembre de 2026
Key finding
The difference in HbA1c levels from baseline to week 26 between the alogliptin and placebo groups was 0.10 (−0.63, 0.83; p = 0.78).
This Phase 3 trial evaluated the efficacy and safety of alogliptin in pediatric patients with type 2 diabetes mellitus, finding no significant difference in HbA1c levels compared to placebo.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This Phase 3 trial evaluated the efficacy and safety of alogliptin in pediatric patients with type 2 diabetes mellitus, finding no significant difference in HbA1c levels compared to placebo.
Clinical relevance
Understanding the efficacy and safety of diabetes medications in children is crucial for developing appropriate treatment plans. This study suggests that alogliptin may not provide additional benefits in controlling blood sugar levels in pediatric patients, highlighting the need for further research into effective treatments for this population.
Keep in mind
The study may have limited generalizability due to its specific population. Effectiveness findings were unclear due to the small difference in HbA1c. The trial duration may not be sufficient to assess long-term effects.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Xuejun VP, Georgeanna K, Daniel SH, et al. Efficacy and Safety of Alogliptin in Pediatric Patients with Type 2 Diabetes Mellitus: A Phase 3 Trial. Diabetes Therapy. 2025;16(5):865-883. doi:10.1007/s13300-025-01700-3
Efectos Principales
No significant difference in HbA1c levels between alogliptin and placebo (0.10%, p = 0.78).
No new safety concerns observed with alogliptin treatment.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Alogliptin 25 mg QD and HbA1c, Safety profile assessment.
This study contributes evidence to
Primary intervention
Alogliptin 25 mg QD
Primary outcomes
- HbA1c
- Safety profile assessment
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
2
Evidence pairs
2
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 55
1
Related topics
2
Evidence pairs
603
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 2 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
HbA1c Reduction
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Safety profile assessment
Alogliptin 25 mg QD → Safety profile assessment
Alogliptin 25 mg QD → Safety profile assessment
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Alogliptin showed no significant change in HbA1c levels (0.10%, p = 0.78).
- Safety assessments revealed no new concerns with alogliptin.
A quién se aplica
- Pediatric patients diagnosed with type 2 diabetes mellitus.
- Participants aged 10-17 years.
Tener en Cuenta
- Findings may not apply to all pediatric populations with diabetes.
- The study's short duration limits long-term efficacy conclusions.
- Further research is needed to explore alternative treatments.
Entre Líneas
- The study may have limited generalizability due to its specific population.
- Effectiveness findings were unclear due to the small difference in HbA1c.
- The trial duration may not be sufficient to assess long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Alogliptin 25 mg QD and HbA1c, Alogliptin 25 mg QD and Safety profile assessment.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Alogliptin 25 mg QD → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Alogliptin 25 mg QD Evidence Hub
All studies on Alogliptin 25 mg QD
1 studies
intervention_hubContributes to Alogliptin 25 mg QD evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
1 studies
outcome_hubMeasures HbA1c as a key outcome.
Safety profile assessment Evidence Hub
All studies measuring Safety profile assessment
1 studies
outcome_hubMeasures Safety profile assessment as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Alogliptin 25 mg QD and HbA1c
Intervention: Alogliptin 25 mg QDOutcome: HbA1c
1 results
All studies on Alogliptin 25 mg QD and Safety profile assessment
Intervention: Alogliptin 25 mg QDOutcome: Safety profile assessment
1 results
All studies on Alogliptin 25 mg QD
Intervention: Alogliptin 25 mg QD
1 results
All studies measuring HbA1c
Outcome: HbA1c
1 results
All studies measuring Safety profile assessment
Outcome: Safety profile assessment
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Alogliptin 25 mg QD lower HbA1c?
Emerging Evidence
Current evidence does not show a clear benefit of Alogliptin 25 mg QD for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Alogliptin 25 mg QD affect safety profile assessment?
Emerging Evidence
Current evidence does not show a clear effect of Alogliptin 25 mg QD on safety profile assessment.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Safety profile assessment
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Adding diabetes medications to metformin improves glycemic control in adults with T2 diabetes.HRS-7535 improves glycemic control in adults with type 2 diabetesLiraglutide and Empagliflozin Improve Heart Function in DiabetesAdding medications improves blood sugar control in diabetes patients.Bariatric surgery improves glucose homeostasis in type 2 diabetes.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.